Compound Detail
CHEMBL3989970
MAVELERTINIB 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL3989970 |
| Name | MAVELERTINIB |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | JYIUNVOCEFIUIU-GHMZBOCLSA-N |
2
Targets
6
Activities
2
Assay Types
27
PK Parameters
20
Publications
3
Known Names
1
Indications
4
Mechanisms
Molecular Properties
415.4
MW (Da)
0.68
ALogP
10
HBA
2
HBD
115.0
PSA (Ų)
0.57
QED
0
Ro5 Violations
6
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Epidermal growth factor receptor erbB1 inhibitor | INHIBITOR | Epidermal growth factor receptor | ✓ | ✓ |
| Epidermal growth factor receptor erbB1 inhibitor | INHIBITOR | Epidermal growth factor receptor | ✓ | ✓ |
| Epidermal growth factor receptor erbB1 inhibitor | INHIBITOR | Epidermal growth factor receptor | ✓ | ✓ |
| Epidermal growth factor receptor erbB1 inhibitor | INHIBITOR | Epidermal growth factor receptor | ✓ | ✓ |
Indications
Carcinoma, Non-Small-Cell Lung
Activity Summary
IC50 5 meas. best 8.52
Ki 1 meas. best 7.89
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Epidermal growth factor receptor CHEMBL203 | IC50 | 8.52 | 7.8125 | 3.0 | 4 |
| Receptor tyrosine-protein kinase erbB-3 CHEMBL5838 | IC50 | 8.4 | 8.4 | 4.0 | 1 |
| Epidermal growth factor receptor CHEMBL203 | Ki | 7.89 | 7.89 | 13.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 8.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 3.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 74.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 141.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 3.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 6.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 196.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 183.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 17.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 53.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 49.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 12.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 3.0 | mL.min-1.kg-1 | Homo sapiens |
| F | 60.0 | % | Mus musculus |
| F | 11.0 | % | Rattus norvegicus |
| F | 66.0 | % | Canis lupus familiaris |
| Fu | 0.2 | - | Mus musculus |
| Fu | 0.22 | - | Rattus norvegicus |
| Fu | 0.75 | - | Canis lupus familiaris |
| Fu | 0.27 | - | Homo sapiens |
| T1/2 | 5.1 | hr | Mus musculus |
| T1/2 | 3.95 | hr | Rattus norvegicus |
| T1/2 | 4.65 | hr | Canis lupus familiaris |
| T1/2 | 5.8 | hr | Homo sapiens |
| T1/2 | 0.56 | hr | Mus musculus |
| T1/2 | 0.28 | hr | Rattus norvegicus |
| T1/2 | 1.3 | hr | Canis lupus familiaris |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | IC50 | = | 3.0 | nM | 8.52 | Inhibition of EGFR T790M/exon 19 deletion mutant phosphorylation in human PC9-DR... | 28287730 |
| Receptor tyrosine-protein kinase erbB-3 | IC50 | = | 4.0 | nM | 8.4 | Inhibition of EGFR L858R mutant phosphorylation in human H3255 cells preincubate... | 28287730 |
| Epidermal growth factor receptor | IC50 | = | 5.0 | nM | 8.3 | Inhibition of EGFR exon 19 deletion mutant phosphorylation in human PC9 cells pr... | 28287730 |
| Epidermal growth factor receptor | IC50 | = | 12.0 | nM | 7.92 | Inhibition of EGFR T790M/L858R double mutant phosphorylation in human H1975 cell... | 28287730 |
| Epidermal growth factor receptor | Ki | = | 13.0 | nM | 7.89 | Inhibition of EGFR T790M/L858R double mutant (unknown origin) | 28287730 |
| Epidermal growth factor receptor | IC50 | = | 307.0 | nM | 6.51 | Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells ... | 28287730 |
Literature References
Data from ChEMBL 36 via Core Engine